Aller au contenu principal
Profil bibliographique

Shawn D. Hingtgen

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

3Publications signalées
0Citations signalées
1Affiliations récentes

Les institutions déclarées

Les domaines associés

Glioma Diagnosis and TreatmentCancer Immunotherapy and BiomarkersExtracellular vesicles in diseaseNanoplatforms for cancer theranosticsCancer Genomics and Diagnostics

Les publications récentes

2026 conference-abstract OpenAlex

Abstract 400: Combinatorial treatment of glioblastoma with temozolomide (TMZ) plus 5-ethynyl-2'-deoxyuridine (EdU).

Humeyra Kaanoglu, Yasemin Kübra Akyel, Adebimpe Adefolaju, Alain Valdivia et autres

Abstract Background: Glioblastoma (GBM) remains highly lethal despite surgery, radiotherapy, and temozolomide (TMZ). We identified a therapeutic role for 5-ethynyl-2′-deoxyuridine (EdU), a thymidine analog whose incorporation is recognized and excised by nucleotide excision repair (NER). We hypothesized that combining TMZ (lesions processed …

us (code pays fourni par la source)

0 citations Cancer Research
2026 conference-abstract OpenAlex

Abstract 661: Rapid CAR T testing in an ex vivo platform that maintains passage-zero patient tumor tissues and their native immunosuppressive microenvironment.

Xiaopei Zhang, Breanna Mann, Adebimpe Adefolaju, Alain Valdivia et autres

Abstract Adoptive T cell therapies, including chimeric antigen receptor (CAR) T cells, have shown limited success in solid tumors, largely due to widespread preclinical models that fail to capture patient tumor heterogeneity and the immunosuppressive tumor microenvironment (TME). Conventional systems, including cell …

us (code pays fourni par la source)

0 citations Cancer Research
2026 conference-abstract OpenAlex

Abstract 653: Rapid drug sensitivity testing of passage-zero patient brain tumor tissues to inform preclinical and clinical decisions: results from a clinical feasibility study.

Breanna Mann, Nichole Artz, Adebimpe Adefolaju, Alain Valdivia et autres

Abstract Functional precision medicine (FPM) offers a promising path forward in neuro-oncology, where genomic profiling alone often fails to predict therapeutic response. To bridge this gap, we developed the Screening Live Cancer Explants (SLiCE) platform, a rapid ex vivo drug screening assay …

us (code pays fourni par la source)

0 citations Cancer Research

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.